Pacific Biosciences Looks Promising As It Targets Low Competition Plant Genome Segment

Pacific Biosciences of California Inc. (PACB) is engaged in developing and manufacturing sequencing systems for solving genetic issues. The company recently developed a new sequencing system for the maize genome, which is expected to pave the way for complex crop as well as livestock genomes. The company used its proprietary SMART technology for this purpose as the technology allows for the real time observation of DNA synthesis. The new development is expected to offer strong boost to the company as it suffered a couple of setbacks in the recent past. The company faces rather tepid response to its new Sequel systems. However, Pacific Biosciences has taken several remedial steps to ensure that Sequel systems gain wider approval in the market. These steps included designing software and chemical updates for the systems. Another major point that goes in the favor of the company that its new sequencing system is mainly designed for plant and livestock segments, which are generally under-served by bigger players such as Thermo Fisher. This may enable Pacific Biosciences in carving a niche for itself in the largely ignored segment of the market.

The company stock has been battered down quite strongly in the market. The steep decline was mainly on account of Roche walking out of its 2013 agreement with Pacific Biosciences. While Roche’s ouster from the collaboration is likely to result in strained liquidity position as well as technological roadblocks, it seems like that Pacific Biosciences is now in position to sustain its position in the market as it continues to add new customers to its roster. The stock is currently trading close to its 52 weeks low as it lost over 55 percent of its value in the past 12 months. Pacific Biosciences is taking up new marketing initiatives to enhance the visibility of its SMART systems in the market. It has added a number of new customers this year,making the long term outlook for the company positive.

Risks

Pacific Biosciences recently announced the pricing of its underwritten public offering at $3.10 apiece. The announcement led to a dip in the stock price, which has recovered since then. The investors need to be careful about the dilutive effect of such offering since the company aims to use the net proceeds for general corporate purposes, instead of boosting its R&D or marketing efforts for any particular drug. However, the dilutive impact of this offering is likely to be limited and is expected to be overshadowed by the overall strength of corporate performance.

1 2
View single page >> |

Subscribe to KKD Healthcare Analytics for an entire Biotech digest. 

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.